Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No, but they battle the same economic headwinds. Market doesn’t want ADF dude. Get real. You can fake it all you want, but reality doesn’t dissolve into the ether.
I’d really like to keep you muted but I can see your ridiculous posts for some reason. Will try once again.
If FDA decreases non ADF quota? Come on. If FDA was to do this they would have done it years ago when opioid crisis was front page news on regular basis with Purdue in limelight. Not happening.
Here comes the applesauce. SequestOx is dead.
Are you completely ignorant? CEO himself said it was shelved.
I don’t need a quote. I know what he said. Scripts aren’t always accurate either. Not worth my time. You will see though all in good time.
He said there was a lack of market for ADT. This means the market doesn’t accept the premium pricing needed above common generic. So you can understand in simplest forms. There will be no feasible revenue or profitability by pursuing the treadmill of ADT they thought SequestOx would open up.
It’s relative and data is several years old. I’d like to see cost comparison today.
CEO stated market didn’t exist for higher ADT pricing. Go back and read the transcripts. SequestOx is a sunk cost. Not being pursued until both FDA and market shifts. It’s all pricing dude.
Yes, they noted their tech was cheaper many years ago. It’s all relative. They also stated demand didn’t exist either. If larger companies can push FDA towards ADT, then fantastic. Elite couldn’t do it on their own. This is the primary reason the company has massive bloat.
SequestOx is shelved buddy. Give it up. You can go back to your government cube now and pretend like world is out against you.
Nothing beyond one day’s liquidity to cover. Nothing material here.
Someone is also at this time putting hamsters up their rear end. Doesn’t mean there is a big market for it. Many more drugs being abused than CNS drugs. CEO has stated that the market can’t support premium for abuse deterrence at reasonable levels. Price is the major factor for providers to select a drug for a patient. Until the FDA actually makes a move towards ADT, common generics will continue to win out. We are playing in this space, are doing fantastic and will continue to have a bright future. I highly doubt an ADT will be approved prior to being acquired.
Each of the drugs in generic form have nothing to do with ADT. Timed release is not ADT. Their tech has not been applied to the CNS drugs. As CEO has stated, SequestOx with the ADT tech has been shelved due to cost, lack of market, etc.
There is no pipeline here. Elite’s tech has been shelved due to both demand, price and cost issues. Elite is a generic, not ADT focused company.
Far too early for buyout to be acceptable for shareholders. I could see it in 2+ years.
The timing of the acceptance isn’t up to Elite. It’s up to the FDA. The timing for when Elite has to file a PR for the acceptance isn’t up to Elite either. That’s per SEC guidelines. None of this has to do with being bogged down with the lawsuit. This is a reporting requirement as a publicly held company.
Third time’s the charm. :)
Wrong board
Why would it not be good? We just launched with Prasco/Burel. I think your penny lift is underestimated based on momentum of the company and what’s in near term pipeline.
Those are paper gains. If you don’t sell, it doesn’t count as income and doesn’t impact 2024 or 2023 contributions (can make 2023 contributions up to when file 2023 taxes).
Not a negative wave. Someone was connecting dots that didn’t exist.
The new packaging facility in the near future will add great benefit to the company, just not happening this month for these open positions.
There’s no need to disregard reality.
165 Ludlow address is their corp address, not the new packaging location. It says posted job was posted on 10/14, before the deal on the new site. Not sure what you are looking at, but the link doesn’t infer anything about hiring at the new location.
Can you walk me through the math of how 100M shares are dumped to the market today when only 2.4M in total shares are traded. It’s a little fuzzy for me.
Interesting about the reasoning behind the 180-day exclusivity period. I wasn’t aware of that. Getting the FDA approval and clearing the legal hurdles would be fantastic. I’m still of frame of mind that Intas is 1st in line as they were the first to invalidate Purdue’s patents. Unless FDA has had enough of their quality control shenanigans. I simply think Purdue is suing anyone on the path to potentially take marketshare. Would love to see otherwise. If we get initial exclusivity. the stock will fly. I’m curious how long it took Intas to battle through this and the time expectation for Elite. I am no lawyer.
Let’s do the same comparison this time next year. Hindsight is always 20/20. Let’s see what your foresight looks like.
Might want to check your math. 500-750M is a significant portion of the ER market. Elite is the contract manufacturer so we don’t get the full enchilada either. CNS is a fragmented market. Prasco/Burel will not get half of it. It’s simply not realistic. Prasco API is now dictated by DEA whereas it wasn’t previously with the authorized generic. Need to temper expectations significantly.
It was a done deal and expected. Today’s PR was more of a formality. Good to see the timing of initial shipment. Just nice to see the validation of the relationship moving forward.
Just ER
That is not correct. 50% of profit splits. Look at where we are making most of our profits. It’s not from the profit splits, it’s from the manufacturing side.
We don’t know the financial impact other than it being material or a PR wouldn’t be required. Looks like we wait until Q3 financials on Feb to get the initial glimpse and Q4 10K in June to get full quarter’s look. By then, we’ll have been moved into the new facility with packing/storage expansion.
Time to break out the “This is our year” mug again. You’ll actually need it for 2024.
To be soon followed by generic CNS filing FDA acceptance. Keep the news coming.
To get on NASDAQ if you can’t get there organically. With tailwinds, this could be a sweet move. But it’s a long-term move, not one if you plan on being acquired in a couple years.
I could see 5-10:1 taking place to ensure we are well above $5 threshold. More likely to take place in 2025.
Wow dude. Easy tiger. Hope this does better than your AMC investment you were pumping for months.
Nothing has changed. Universities are always doing pharma research. I think Weezuhl’s insight is interesting in the pharma justification of the global pricing model, which is broken.
Agreed, 100% stupid. That is completely against American innovation train and engine for R&D.
That timing has zero impact right now. Everyone got CRLs. Plus, we were one of many back then as everyone had to do the insufflation study. We are also one of many now. Per last cc, no questions have been asked yet on the opioid filing, but does expect them soon. He did say that he expects approval later in the year. I’m expecting the filing wasn’t soon enough.
Also depends on whether we get first to file for generic oxy. Don’t think so, but that would add some serious fuel to the fire.
Prior to $5 share price being hit organically? Absolutely.